Integrated Biopharma Inc
Integrated BioPharma, Inc., together with its subsidiaries, engages in the manufacturing, distributing, marketing and sale of vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. The company operates through two segments, Contract Manufacturing and Other Business Lines. The Contract Manufacturing segment manufactures vitamins and nutritional supple… Read more
Integrated Biopharma Inc (INBP) - Net Assets
Latest net assets as of September 2025: $20.49 Million USD
Based on the latest financial reports, Integrated Biopharma Inc (INBP) has net assets worth $20.49 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.54 Million) and total liabilities ($5.05 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $20.49 Million |
| % of Total Assets | 80.22% |
| Annual Growth Rate | 4.75% |
| 5-Year Change | 41.74% |
| 10-Year Change | N/A |
| Growth Volatility | 81.64 |
Integrated Biopharma Inc - Net Assets Trend (2000–2025)
This chart illustrates how Integrated Biopharma Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Integrated Biopharma Inc (2000–2025)
The table below shows the annual net assets of Integrated Biopharma Inc from 2000 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | $20.32 Million | +5.61% |
| 2024-06-30 | $19.24 Million | +2.00% |
| 2023-06-30 | $18.86 Million | +1.54% |
| 2022-06-30 | $18.57 Million | +29.59% |
| 2021-06-30 | $14.33 Million | +136.26% |
| 2020-06-30 | $6.07 Million | +220.50% |
| 2019-06-30 | $1.89 Million | +136.15% |
| 2018-06-30 | $-5.24 Million | +11.69% |
| 2017-06-30 | $-5.93 Million | +28.80% |
| 2016-06-30 | $-8.33 Million | +10.62% |
| 2015-06-30 | $-9.32 Million | +8.26% |
| 2014-06-30 | $-10.15 Million | +1.31% |
| 2013-06-30 | $-10.29 Million | +0.90% |
| 2012-06-30 | $-10.38 Million | -34.93% |
| 2011-06-30 | $-7.70 Million | -35.09% |
| 2010-06-30 | $-5.70 Million | -132.87% |
| 2009-06-30 | $-2.45 Million | -122.52% |
| 2008-06-30 | $10.86 Million | -45.68% |
| 2007-06-30 | $20.00 Million | -22.29% |
| 2006-06-30 | $25.73 Million | +61.13% |
| 2005-06-30 | $15.97 Million | -34.54% |
| 2004-06-30 | $24.40 Million | +33.65% |
| 2003-06-30 | $18.25 Million | +140.67% |
| 2002-06-30 | $7.58 Million | +22.50% |
| 2001-06-30 | $6.19 Million | -2.84% |
| 2000-06-30 | $6.37 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Integrated Biopharma Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2134.9% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $51.74 Million | 254.64% |
| Total Equity | $20.32 Million | 100.00% |
Integrated Biopharma Inc Competitors by Market Cap
The table below lists competitors of Integrated Biopharma Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
APPLIED MATERIALS (AP2.SG)
STU:AP2
|
$2.83 Million |
|
AVI Global Trust PLC
LSE:AGT
|
$2.83 Million |
|
Swiftmerge Acquisition Corp. Warrants
NASDAQ:IVCPW
|
$2.83 Million |
|
Metalex Ventures Ltd
PINK:MXTLF
|
$2.84 Million |
|
North Stawell Minerals Ltd
AU:NSM
|
$2.83 Million |
|
Infracommerce CXaaS S.A
SA:IFCM3
|
$2.83 Million |
|
STRYKER - Dusseldorf Stock Exchang
DU:SYK
|
$2.83 Million |
|
Fertoz Ltd
AU:FTZ
|
$2.83 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Integrated Biopharma Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 19,238,000 to 20,317,000, a change of 1,079,000 (5.6%).
- Net income of 808,000 contributed positively to equity growth.
- Other factors increased equity by 271,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $808.00K | +3.98% |
| Other Changes | $271.00K | +1.33% |
| Total Change | $- | 5.61% |
Book Value vs Market Value Analysis
This analysis compares Integrated Biopharma Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.44x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-06-30 | $-0.48 | $0.29 | x |
| 2015-06-30 | $-0.44 | $0.29 | x |
| 2016-06-30 | $-0.39 | $0.29 | x |
| 2017-06-30 | $-0.28 | $0.29 | x |
| 2018-06-30 | $-0.25 | $0.29 | x |
| 2019-06-30 | $0.06 | $0.29 | x |
| 2020-06-30 | $0.20 | $0.29 | x |
| 2021-06-30 | $0.48 | $0.29 | x |
| 2022-06-30 | $0.62 | $0.29 | x |
| 2023-06-30 | $0.63 | $0.29 | x |
| 2024-06-30 | $0.64 | $0.29 | x |
| 2025-06-30 | $0.65 | $0.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Integrated Biopharma Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.98%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 1.49%
- • Asset Turnover: 2.18x
- • Equity Multiplier: 1.23x
- Recent ROE (3.98%) is below the historical average (21.46%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 49.33% | 17.49% | 2.09x | 1.35x | $2.51 Million |
| 2002 | 18.37% | 5.92% | 2.35x | 1.32x | $634.50K |
| 2003 | 4.90% | 4.02% | 1.07x | 1.14x | $-931.50K |
| 2006 | 32.97% | 14.58% | 1.54x | 1.47x | $5.87 Million |
| 2014 | 0.00% | 0.39% | 2.91x | 0.00x | $1.15 Million |
| 2015 | 0.00% | 1.96% | 3.23x | 0.00x | $1.67 Million |
| 2016 | 0.00% | 2.27% | 3.00x | 0.00x | $1.79 Million |
| 2017 | 0.00% | 5.00% | 3.09x | 0.00x | $2.94 Million |
| 2018 | 0.00% | 1.55% | 3.00x | 0.00x | $1.20 Million |
| 2019 | 89.17% | 3.38% | 2.53x | 10.45x | $1.50 Million |
| 2020 | 67.71% | 7.78% | 2.30x | 3.78x | $3.50 Million |
| 2021 | 55.90% | 12.61% | 2.50x | 1.77x | $6.58 Million |
| 2022 | 20.66% | 6.82% | 2.23x | 1.36x | $1.98 Million |
| 2023 | -0.18% | -0.07% | 1.99x | 1.35x | $-1.92 Million |
| 2024 | 0.58% | 0.22% | 1.92x | 1.36x | $-1.81 Million |
| 2025 | 3.98% | 1.49% | 2.18x | 1.23x | $-1.22 Million |
Industry Comparison
This section compares Integrated Biopharma Inc's net assets metrics with peer companies in the Packaged Foods industry.
Industry Context
- Industry: Packaged Foods
- Average net assets among peers: $5,681,533,529
- Average return on equity (ROE) among peers: 0.04%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Integrated Biopharma Inc (INBP) | $20.49 Million | 49.33% | 0.25x | $2.83 Million |
| Above Food Ingredients Inc. Common Stock (ABVE) | $30.90K | -3.31% | 7.66x | $18.76 Million |
| The a2 Milk Company Limited (ACOPF) | $7.27 Million | -30.19% | 0.14x | $3.91 Billion |
| Ayujoy Herbals Ltd (AJOY) | $22.20 Million | 29.29% | 0.00x | $95.71 |
| Alfa S.A.B. de C.V (ALFFF) | $53.35 Billion | 7.36% | 3.80x | $2.16 Billion |
| Amincor Inc (AMNCB) | $34.44 Million | -63.76% | 0.81x | $2.24K |
| Armanino Foods New (AMNF) | $21.40 Million | 30.30% | 0.33x | $72.33K |
| Amira Nature Foods Ltd (ANFIF) | $303.22 Million | 8.27% | 0.89x | $128.79 |
| AAK AB (publ.) (ARHUF) | $2.44 Billion | 12.85% | 2.63x | $5.07 Billion |
| Artisan Consumer Goods Inc (ARRT) | $-326.75K | 0.00% | 0.00x | $279.39K |
| ARYZTA AG (ARZTF) | $632.10 Million | 9.58% | 2.04x | $53.13 Million |